top of page

April 2021 // Communication

Lichtsteiner Foundation Testimonial Film about Synendos

We are delighted to share the testimonial film created by the Lichtsteiner Foundation. Co-founder and CEO Andrea Chicca gives insights into entrepreneurship, Synendos and its breakthrough approach to treat unmet needs in CNS disorders.

Many thanks to Lichtsteiner Foundation for this great opportunity and their support!

Recent Posts

See All

January 2024 // Company & Communication

Synendos granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510. Synendos transitions to a clinical-stage biotech company developing innovative Endocanna

July 2023 // Communication

Synendos Therapeutics AG announces that co-founder and Scientific Advisor Board member, Professor Jürg Gertsch, presented groundbreaking new findings on an endocannabinoid transporter at the 10th Gord


bottom of page